MedTrace Logo

Expanded Access to Fosmanogepix for Patients With Serious or Life-threatening Invasive Fungal Infections

NCT06433128 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2025-07-24

No results posted yet for this study

Summary

The EAP is intended to provide a treatment option for patients with proven or probable serious or life-threatening invasive fungal infection (in accordance with the EORTC-MSGERC criteria) who have exhausted their treatment options, primarily due to an infection with a resistant fungal pathogen, and for whom no other treatment options are available through marketed drugs or investigational agents in clinical studies ongoing in the respective indication.

Conditions

  • Invasive Fungal Infections

Interventions

DRUG

Fosmanogepix solution for infusion

Fosmanogepix solution for infusion, 20 mg/mL for intravenous administration

DRUG

Fosmanogepix 400 mg tablets

Fosmanogepix 400 mg tablets for oral administration

Sponsors & Collaborators

  • Basilea Pharmaceutica

    lead INDUSTRY

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06433128 on ClinicalTrials.gov